BioNTech

BNTX

Market cap $25.3B

On Sept. 30, Pfizer announced a deal with the U.S. government that will allow the pharmaceutical leader to avoid President Donald Trump's tariffs for three years in exchange for slashing the prices of certain drugs in the U.S. and investing in local manufacturing efforts. This deal lifted not only Pfizer, but also much of the healthcare sector, especially the company's drugmaking peers, as Wall Street expects more deals along those lines.

BioNTech SE, InstaDeep Ltd - Special Call Company Participants Ugur Sahin - Co-Founder, CEO & Chair of the Management Board Karim Beguir Alexandre Laterre Bernardo Almeida Bora Guloglu Nicolas Lopez Carranza Youssef Ben Dhieb Cheng Zhang Antoine Delaunay Conference Call Participants Lexi Walls Michael Rooney Michael Pye - Baillie Gifford Overseas Limited Presentation Unknown Executive Hi. Good afternoon, everybody.

Germany-based BioNTech (BNTX 3.64%) saw its U.S. listed stock enjoy a mini-pop on Wednesday, and for once this wasn't largely based on the Comirnaty COVID-19 vaccine it developed with Pfizer. Rather, investors seemed to be cheered by the biotech's continuing efforts to harness artificial intelligence (AI) technology.

MAINZ, Germany, September 23, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”), alongside its artificial intelligence (“AI”) company InstaDeep Ltd. (“InstaDeep”), will host its second AI Day, an edition of BioNTech's “Innovation Series”, at 09:00 a.m. EDT (3:00 p.m. CEST) on Wednesday, October 1, 2025, in London, United Kingdom. The event will provide an overview of BioNTech's AI strategy and capabilities, and the application of AI in BioNTech's pipeline and internal processes.

A victory on the regulatory front and a bullish analyst move were the twin news items propelling BioNTech's (BNTX 2.52%) shares higher as the stock trading week began on Monday. The Germany-based biotech's equity rose by almost 3% in value during the session, comparing well to the 0.4% improvement of the S&P 500 index.

Jared Holz, Mizuho healthcare senior strategist, joins CNBC's 'Squawk on the Street' to discuss outlooks on pharmaceuticals, what new government vaccine panel recommendations mean for the stocks, and much more.

The reworked ACIP will make its debut Friday when the panelists weigh the suite of new Covid boosters from Pfizer, Moderna and Novavax.

MRNA, BNTX, PFE and NVAX stocks fall as health officials reportedly plan to link COVID-19 vaccines to child deaths ahead of a key CDC meeting.

A star stock during the pandemic era wasn't shining so brightly on Friday. On a media report that the current presidential administration is preparing to link a set of fatalities to Covid vaccines, BioNTech's (BNTX -7.35%) share price declined by 7% across that day's trading session.

Shares of companies that make COVID vaccines sank Friday, after a report raised fears that Trump administration health officials will blame the vaccines for some child deaths.